Artiva Biotherapeutics Files for IPO

Ticker: ARTV · Form: S-1 · Filed: Jun 28, 2024 · CIK: 1817241

Artiva Biotherapeutics, Inc. S-1 Filing Summary
FieldDetail
CompanyArtiva Biotherapeutics, Inc. (ARTV)
Form TypeS-1
Filed DateJun 28, 2024
Risk Levelmedium
Pages15
Reading Time18 min
Key Dollar Amounts$160 billion, $1 million, $100,000, $6,000
Sentimentneutral

Sentiment: neutral

Topics: ipo, biotech, oncology, registration-statement

TL;DR

Artiva Biotherapeutics files S-1 for IPO, aiming to fund its cancer therapy pipeline.

AI Summary

Artiva Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, filed an S-1 registration statement on June 28, 2024, to potentially offer shares of its common stock. The company is focused on developing novel immunotherapies for cancer, with its lead product candidate, AB-101, targeting solid tumors. The filing indicates a planned initial public offering, though specific dollar amounts and share prices are not yet detailed.

Why It Matters

This S-1 filing signals Artiva Biotherapeutics' intention to go public, which could provide significant capital for its cancer therapy research and development, potentially impacting the future of oncology treatments.

Risk Assessment

Risk Level: medium — As a clinical-stage biopharmaceutical company, Artiva Biotherapeutics faces inherent risks related to drug development, regulatory approval, and market adoption.

Key Numbers

  • 333-280568 — SEC File Number (Identifies this specific registration statement)
  • 0001817241 — Central Index Key (Unique identifier for Artiva Biotherapeutics in SEC filings)
  • 2836 — SIC Code (Industry classification for Biological Products)

Key Players & Entities

  • Artiva Biotherapeutics, Inc. (company) — Registrant
  • AB-101 (drug_candidate) — Lead product candidate
  • Fred Aslan, M.D. (person) — President and Chief Executive Officer
  • Jennifer Bush (person) — Chief Operating Officer
  • Carlos Ramirez (person) — Legal Counsel
  • Charles S. Kim (person) — Legal Counsel
  • Cooley LLP (company) — Legal Counsel
  • Delaware (jurisdiction) — State of incorporation
  • San Diego, CA (location) — Principal executive offices

FAQ

What is the primary purpose of this S-1 filing?

The S-1 filing is a registration statement filed with the SEC to register shares of common stock for a potential initial public offering (IPO).

What is Artiva Biotherapeutics' main focus?

Artiva Biotherapeutics is a clinical-stage biopharmaceutical company focused on developing novel immunotherapies for cancer, with a lead candidate AB-101.

Where are Artiva Biotherapeutics' principal executive offices located?

The company's principal executive offices are located at 5505 Morehouse Drive, Suite 100, San Diego, CA 92121.

Who are the key individuals mentioned in the filing's contact information?

Key individuals mentioned include Fred Aslan, M.D. (President and CEO), Jennifer Bush (Chief Operating Officer), and legal representatives Carlos Ramirez and Charles S. Kim from Cooley LLP.

What is the state of incorporation for Artiva Biotherapeutics?

Artiva Biotherapeutics, Inc. is incorporated in Delaware.

Filing Stats: 4,418 words · 18 min read · ~15 pages · Grade level 16.7 · Accepted 2024-06-28 16:04:19

Key Financial Figures

  • $160 billion — for which in 2023 reached approximately $160 billion and represent the second-largest class
  • $1 million — an incremental financial burden of over $1 million per patient. The scalability of our pro
  • $100,000 — acture auto-CAR-Ts is estimated at over $100,000 per treatment course, limiting flexibil
  • $6,000 — AlloNKs COGS per patient would be below $6,000, an order of magnitude below the curren

Filing Documents

RISK FACTORS

RISK FACTORS 13 SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS 79 INDUSTRY AND OTHER DATA 81 DIVIDEND POLICY 82

USE OF PROCEEDS

USE OF PROCEEDS 83 CAPITALIZATION 85

MANAGEMENTS DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

MANAGEMENTS DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS 90

BUSINESS

BUSINESS 112 MANAGEMENT 169 EXECUTIVE AND DIRECTOR COMPENSATION 177 CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS 195 PRINCIPAL STOCKHOLDERS 200

DESCRIPTION OF CAPITAL STOCK

DESCRIPTION OF CAPITAL STOCK 203 SHARES ELIGIBLE FOR FUTURE SALE 208 MATERIAL U.S. FEDERAL INCOME TAX CONSIDERATIONS FOR NON-U.S. HOLDERS 210

UNDERWRITING

UNDERWRITING 214 LEGAL MATTERS 223 EXPERTS 223 WHERE YOU CAN FIND MORE INFORMATION 223 INDEX TO FINANCIAL STATEMENTS F-1 We and the underwriters have not authorized anyone to provide any information or to make any representations other than those contained in this prospectus or in any free writing prospectuses we have prepared. We and the underwriters take no responsibility for, and can provide no assurance as to the reliability of, any other information that others may provide you. We are offering to sell, and seeking offers to buy, shares of common stock only in jurisdictions where offers and sales are permitted. The information contained in this prospectus is accurate only as of the date of this prospectus, regardless of the time of delivery of this prospectus or of any sale of the common stock. For investors outside the United States: Neither we nor the underwriters have done anything that would permit this offering, or the possession or distribution of this prospectus, in any jurisdiction where action for those purposes is required, other than in the United States. Persons outside the United States who come into possession of this prospectus must inform themselves about, and observe any restrictions relating to, this offering of common stock and the distribution of this prospectus outside the United States. Table of Contents PROSPECTUS SUMMARY This summary highlights information contained elsewhere in this prospectus. This summary does not contain all of the information you should consider before investing in our common stock. Before investing in our common stock, you should read this entire prospectus carefully, especially the sections titled Risk Factors, Special Note Regarding Forward-Looking Statements, and Managements Discussion and Analysis of Financial Condition and Results of Operations, and our financial statements and the related notes appearing elsewhere in this prospectus. As used in this prospectus, unless the context ot

View Full Filing

View this S-1 filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.